T.C

[T.C @TechnologyTeech]

@CrowHater1 Jepp

[T.C @TechnologyTeech]

#Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer #canta

[T.C @TechnologyTeech]

@jonteviggo @MrAdde

[Market Shriek @MarketShriek]

$TRVX: Targovax ASA has agreed to the terms and conditions for a convertible bond facility with Atlas Special Opportunities which will secure financing of up to gross NOK 300 million over three years.

[T.C @TechnologyTeech]

@jonteviggo

[T.C @TechnologyTeech]

@Coolbreez016 @thor_chr KONK.

[T.C @TechnologyTeech]

Vaultavo Introduces Biometric Smart Card Based Crypto Custody Solution

https://t.co/uqwZ0B2ZUh

[T.C @TechnologyTeech]

Card payment with a biometric card via fingerprint.

https://t.co/gsorKH0kT4

[T.C @TechnologyTeech]

BNP Paribas attracts and onboards new premium customers in the first large-scale commercial launch of the #biometric payment card 💳

https://t.co/uBR4d3Iuxh

[T.C @TechnologyTeech]

#Oncopeptides #Onco +10%

[T.C @TechnologyTeech]

https://t.co/UoBEdpBkz5

#Fing #Fpc

[T.C @TechnologyTeech]

#Fpc #Fing

[T.C @TechnologyTeech]

Gyros Protein Technologies @GyrosProteinTec installed a Symphony® X instrument in #Oncopeptides AB (publ) @oncopeptides_ab lab in Stockholm, Solna.

https://t.co/m3T4UMMSM5

[Cision News @CisionNews]

Cantargia announces appointment of Patrik Renblad as Chief Financial Officer https://t.co/JOjggkCmxv

[T.C @TechnologyTeech]

#Cantargia completes toxicity study of #CAN10 antibody
The CAN10 antibody was found to be well tolerated when administered over six weeks in the trial.

https://t.co/KxPUCIdqmc

[T.C @TechnologyTeech]

@snappaupp @RS6HK605

[T.C @TechnologyTeech]

@LockerRoomLOL

[T.C @TechnologyTeech]

#DNB We have tweaked our cost
estimates and reiterate our BUY and SEK28 target price. $ONCO #ONCOPEPTIDES

[T.C @TechnologyTeech]

New to 2023! Take the next step in your career, as a Medical Science Liaison with @SyneosHealth in partnership @Oncopeptides. success of your team across Europe! Apply today! #Careers #medicalscienceliaison

3 #ONCO #Oncopeptides (MSL) jobs found

https://t.co/AJYV6blqDU

[T.C @TechnologyTeech]

#DNB... Launch in Germany The Q3 report contained no big surprises. While SG&A
costs were above our estimate, this is explained by the
start of EU commercialisation. The company indicated a
target population in the region implying cUSD150m–
200m in annual revenues